MODERATO
To demonstrate the non-inferiority at 96 weeks of a strategy involving a switch to a two-drug regimen consisting of DTG + 3TC or ATV/r + 3TC compared with the WHO-recommended triple-therapy regimen of TDF + 3TC + EFV or DTG in patients who have maintained virologic success for at least two years on TDF + XTC + EFV or DTG
Project Details
Principal Investigator
- South (Serge Eholié), North (Roland Landman)
Chef de Projet
- Fatou Fadiga
Participating Countries
- • Ivory Coast
- • Cameroon
- • Burkina Faso
Duration
72 months
Sponsor
ANRS MIE
Objectives
Main Objectives
Research Team
The research team has not yet been filled in for this project.
Collaborate with us
We are open to partnerships with international research institutions and doctoral students.
Estimated response time: 3-5 business days.
